TRTL-913 (GABA-A positive allosteric modulator) Phase 2a for tinnitus
Trial details
- Registry identifier: NCT07777549 on ClinicalTrials.gov
- Phase: Phase 2a
- Status: Not yet recruiting (est. start Sept 2026)
- Sponsor: Tortugas Neuroscience
- Planned enrollment: 100
- Estimated completion: Aug 2027
- Country: USA
Why this trial matters
A Phase 2a drug trial targeting tinnitus as the primary indication. Part A doses healthy volunteers (double-blind, placebo-controlled); only Part B is in adults with tinnitus, and it is open-label with safety as the primary outcome (registry record updated 20 August 2026). Tortugas launched April 2026 with $106M to develop the ex-Hansoh compound.
Related treatment evidence
Trial statuses are verified against the ClinicalTrials.gov registry by our weekly automated check. A tracked trial is research in progress — inclusion is not a treatment recommendation, and only the study team can determine eligibility.